Veracyte, Inc.
VCYT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $446 | $361 | $297 | $220 |
| % Growth | 23.5% | 21.8% | 35.1% | – |
| Cost of Goods Sold | $148 | $113 | $102 | $74 |
| Gross Profit | $298 | $248 | $195 | $145 |
| % Margin | 66.9% | 68.7% | 65.7% | 66.1% |
| R&D Expenses | $69 | $57 | $41 | $30 |
| G&A Expenses | $178 | $158 | $77 | $101 |
| SG&A Expenses | $206 | $184 | $174 | $181 |
| Sales & Mktg Exp. | $28 | $27 | $98 | $80 |
| Other Operating Expenses | $7 | $92 | $21 | $16 |
| Operating Expenses | $282 | $334 | $236 | $227 |
| Operating Income | $16 | -$86 | -$41 | -$82 |
| % Margin | 3.6% | -23.8% | -13.9% | -37.3% |
| Other Income/Exp. Net | $10 | $9 | $5 | $0 |
| Pre-Tax Income | $26 | -$77 | -$36 | -$82 |
| Tax Expense | $2 | -$2 | $0 | -$6 |
| Net Income | $24 | -$74 | -$37 | -$76 |
| % Margin | 5.4% | -20.6% | -12.3% | -34.4% |
| EPS | 0.32 | -1.02 | -0.51 | -1.11 |
| % Growth | 131.4% | -100% | 54.1% | – |
| EPS Diluted | 0.31 | -1.02 | -0.51 | -1.11 |
| Weighted Avg Shares Out | 76 | 73 | 72 | 68 |
| Weighted Avg Shares Out Dil | 78 | 73 | 72 | 68 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $7 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $23 | $27 | $29 | $21 |
| EBITDA | $49 | -$49 | -$7 | -$60 |
| % Margin | 11% | -13.7% | -2.4% | -27.4% |